

AMENDMENTS TO THE CLAIMS

Claims 1 (**WITHDRAWN**)

Claims 2-52 (**CANCELLED**)

Claims 53-80 (**WITHDRAWN**)

81. (**Currently Amended**) A GDF-8 analogue derived from an animal GDF-8 polypeptide comprising SEQ ID NO: 11 or 12, which ~~that~~ has been modified by substituting at least one first amino acid sequence in SEQ ID NO: 11 or 12 with at least one second amino acid sequence which comprises a foreign T_H epitope, wherein said first amino acid sequence is from one or more of residues 1-12, 18-41, 43-48, 49-69 or 79-104 in SEQ ID NO: 11 or 12, wherein the number of amino acid substitutions does not exceed 60.

82. An immunogenic composition comprising an immunologically effective amount of a DGF-8 analogue according to claim 81, the composition further comprising a pharmaceutically and immunologically acceptable carrier and/or vehicle and optionally an adjuvant.

83. An immunogenic composition according to claim 82, wherein the adjuvant is selected from the group consisting of the adjuvants of claim 73.

Claims 84-102 (**WITHDRAWN**)

103. (**Currently Amended**) A GDF-8 analogue derived from an animal GDF-8 polypeptide comprising SEQ ID NO: 11 or 12, which ~~that~~ has been modified by substituting at least one first amino acid sequence in SEQ ID NO: 12 with at least one second amino acid sequence which comprises a foreign T_H epitope, wherein said first amino acid sequence is from one or more of residues 1-12, 18-41, 43-48, 49-69 or 79-104 in SEQ ID NO: 12, wherein the number of amino acid substitutions does not exceed 60.

104. The GDF-8 analogue according to claim 103, wherein the modification is made in residues 18-41 of SEQ ID NO: 12.

105. **(NEW)** A GDF-8 analogue derived from an animal GDF-8 polypeptide comprising SEQ ID NO: 11 or 12, wherein said animal GDF-8 polypeptide has been modified by

- introducing a foreign T helper epitope (T_H epitope) at any one of residues 18-41, 49-69, or 79-104 in SEQ ID NO: 11 or 12 by means of amino acid deletion, insertion, or substitution,
 - introducing a foreign T_H epitope at the N- or C-terminus to SEQ ID NO: 11 or 12 by means of addition, or
 - introducing a foreign T_H epitope into any one of the loop areas or the flexible termini in the GDF-8 polypeptide by means of insertion or substitution,
- wherein the number of amino acid additions, insertions, deletions, and substitutions does not exceed 60.

106. **(NEW)** The method according to claim 106, wherein the foreign T_H epitope is introduced by means of insertion.

107. **(NEW)** The method according to claim 106, wherein the foreign T_H epitope is introduced by means of addition.

108. **(NEW)** The method according to claim 106, wherein the foreign T_H epitope is introduced by means of substitution.

109. **(NEW)** The method according to claim 106, wherein the foreign T_H epitope is promiscuous.

110. **(NEW)** An immunogenic composition comprising an immunologically effective amount of a GDF-8 analogue according to claim 105, the composition further comprising a pharmaceutically and immunologically acceptable carrier and/or vehicle and optionally an adjuvant.